DaVita Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- DaVita Inc. DaVita Inc. provides kidney care services, primarily dialysis treatments for patients with chronic kidney failure and end-stage kidney disease; operates approximately 2,675 outpatient dialysis centers in the United States serving more than 200,000 patients and 367 centers in 11 other countries serving around 49,400 patients; offers related laboratory services, including routine tests for dialysis patients and other physician-prescribed tests; delivers home-based hemodialysis, hospital inpatient dialysis, and acute inpatient dialysis services; provides integrated kidney care and disease management through DaVita Integrated Kidney Care for risk-based arrangements; conducts clinical research via DaVita Clinical Research since 1985 across pharmaceutical and medical device development; supports nephrologists with technology solutions through DaVita Physician Solutions; and develops innovative health care solutions for kidney disease patients through DaVita Venture Group. The company, incorporated in 1994 and formerly known as DaVita HealthCare Partners Inc. until a 2016 name change, maintains world headquarters in Denver, Colorado, and generates the majority of revenues from Medicare and government-based programs while targeting commercial payers for higher margins; it holds a 37% share of the U.S. dialysis market and operates internationally across regions including Latin America, Europe, and Asia. DaVita Inc. recently expanded internationally through 2024 acquisitions from Fresenius Medical Care for $300 million, adding over 270 clinics in Brazil, Colombia, Chile, and Ecuador to become Latin America's largest dialysis provider; entered new markets in Ecuador and Chile while deepening presence in Colombia; refinanced debt with a new $1.9 billion Term Loan B-2 and $3.5 billion credit facilities including a $2 billion Term Loan A-2 and $1.5 billion revolving facility in 2025; issued $1 billion in senior notes due 2033; and reported Q3 2025 revenues of $3.42 billion amid volume challenges from flu season, Hurricane Helene, and a cyber incident.
Company News
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
Do Options Traders Know Something About DaVita Stock We Don't?
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
Alebund Pharmaceuticals Announces 2026 Interim Results
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
2,460,987 Shares in DaVita Inc. $DVA Purchased by BlackRock Inc.
Bank of New York Mellon Corp Makes New $101.13 Million Investment in DaVita Inc. $DVA
Bank of America Corp DE Cuts Holdings in DaVita Inc. $DVA
Is DaVita (DVA) a Great Value Stock Right Now?
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
Dow Extends Record Run With Over 400-Point Pop
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita Q2 Earnings Call Highlights
DaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic Execution Drive Confidence
DaVita Inc. (DVA) Q2 2026 Earnings Call Transcript
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
Is DaVita Inc (DVA) Overvalued After Q2 Earnings Beat? EPS at $4.02 and Revenue at $3.554 Billion; GF Score: 86/100